GIPR Program

About Orion Biotechnology

Orion Biotechnology is a preclinical-stage biotech company developing first-in-class GPCR-targeted therapies for obesity and metabolic diseases. Its core asset is the PROcisionX™ platform, which integrates phage display, multiplex chemical synthesis, and structure-activity analysis to generate optimized drug candidates in under six months. The company is advancing two lead candidates against the novel target GPR75 towards clinical development, led by a seasoned management team with deep pharmaceutical industry experience.

Therapeutic Areas